Revenue from Contracts with Customers

3 Months Ended

Jul. 31, 2023

Revenue from Contract with Customer [Abstract]

Revenue from Contracts with Customers

Revenue from Contracts with Customers

Oncology Services Revenue

The following tables represents disaggregated revenue for the three months ended July 31, 2023 and 2022:

	Three Months Ended July 31,
	2023		2022
Pharmacology services	$	11,860	$	12,756
Other TOS revenue	684		948
Personalized oncology services	17		41
Total oncology services revenue	$	12,561	$	13,745

Other Translational Oncology Solutions ("TOS") revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers, specifically flow cytometry services and software-as-a-service ("SaaS") provided via our Lumin Bioinformatics software ("Lumin").

Contract Balances

Contract assets include unbilled amounts typically resulting from revenue recognized in excess of the amounts billed to the customer for which the right to payment is subject to factors other than the passage of time. These amounts may not exceed their net realizable value. Contract assets are classified as current and included in accounts receivable. Contract liabilities consist of customer payments received in advance of performance and billings in excess of revenue recognized, net of revenue recognized from the balance at the beginning of the period and included in deferred revenue. Contract assets and liabilities are presented on the balance sheet on a net contract-by-contract basis at the end of each reporting period.